Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18226969 | 0.94 | DPP4 (0.39) | DPP4 | |
| SCHEMBL4826854 | 0.88 | DPP4 (0.39) | DPP4 | |
| SCHEMBL30149683 | 0.88 | DPP4 (0.39) | DPP4 | |
| SCHEMBL30441973 | 0.81 | DPP4 (0.33) | DPP4 | |
| SCHEMBL29545980 | 0.81 | KDM1A (0.41) | DPP4 | |
| SCHEMBL377065 | 0.81 | KDM1A (0.41) | DPP4 | |
| SCHEMBL16860902 | 0.81 | DPP4 (0.33) | DPP4 | |
| SCHEMBL1262764 | 0.81 | DPP4 (0.33) | DPP4 | |
| SCHEMBL19433173 | 0.79 | DPP4 (0.36) | DPP4 | |
| SCHEMBL693457 | 0.79 | GPR84 (0.37) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 551 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119465288-A | Anion exchange membrane, preparation method and application thereof, and electrolysis device | 氢和元泰(常州)新材料科技有限公司 | 2025-02-18 | — | — | CN | claimed |
| CN-114605223-B | Method for preparing 2,4, 5-trifluoro-benzyl bromide by using 2,4, 5-trifluoro-benzyl chloride | 浙江永太科技股份有限公司 | 2024-03-15 | — | — | CN | claimed |
| CN-220496319-U | 2,4, 5-trifluoro benzyl bromide production system | 宁夏华昊生物科技有限公司 | 2024-02-20 | — | — | CN | claimed |
| CN-114805314-B | Synthesis method of Entecavir | 杭州国瑞生物科技有限公司 | 2023-12-15 | — | — | CN | claimed |
| WO-2023201802-A1 | SYNTHESIS METHOD FOR ENSITRELVIR | 杭州国瑞生物科技有限公司 | 2023-10-26 | — | — | WO | claimed |
| CN-116924884-A | Preparation method of 2,4, 5-trifluoro-benzyl bromide | 安庆朗坤药业有限公司 | 2023-10-24 | — | — | CN | claimed |
| CN-114644621-B | Preparation method of oral medicine S-217622 for treating new coronaries pneumonia | 苏州立新制药有限公司 | 2023-08-22 | — | — | CN | claimed |
| CN-114853560-B | Preparation method of 2,4, 5-trifluoro-benzyl bromide and 2,4, 5-trifluoro-benzoic acid | 湖南复瑞生物医药技术有限责任公司 | 2023-04-21 | — | — | CN | claimed |
| CN-114853560-A | Preparation method of 2,4, 5-trifluorobenzyl bromide and 2,4, 5-trifluorobenzoic acid | 湖南复瑞生物医药技术有限责任公司 | 2022-08-05 | — | — | CN | claimed |
| CN-114805314-A | Synthesis method of Ensaitevir | 杭州国瑞生物科技有限公司 | 2022-07-29 | — | — | CN | claimed |
| CN-114773149-A | Efficient synthesis method of medicine intermediate 2,4, 5-trifluorobromobenzyl | 浙江解氏新材料股份有限公司 | 2022-07-22 | — | — | CN | claimed |
| CN-114773147-A | Preparation method of 2,4, 5-trifluorobenzyl bromide | 浙江永太科技股份有限公司 | 2022-07-22 | — | — | CN | claimed |
| CN-114644621-A | Preparation method of oral medicine S-217622 for treating neocoronary pneumonia | 苏州立新制药有限公司 | 2022-06-21 | — | — | CN | claimed |
| CN-114605223-A | Method for preparing 2,4, 5-trifluorobenzyl bromide by using 2,4, 5-trifluorobenzyl chloride | 浙江永太科技股份有限公司 | 2022-06-10 | — | — | CN | claimed |
| CN-114591141-A | Preparation method of 2,4, 5-trifluorobenzyl bromide | 浙江永太科技股份有限公司 | 2022-06-07 | — | — | CN | claimed |
| CN-108314688-B | A kind of synthetic method of sitagliptin | 安徽海康药业有限责任公司 | 2019-08-06 | — | — | CN | claimed |
| CN-108314688-A | A kind of synthetic method of sitagliptin | 安徽海康药业有限责任公司 | 2018-07-24 | — | — | CN | claimed |
| CN-104987338-A | Low cost method for preparing sitagliptin phosphate salt key intermediate | XINFA PHARMACEUTICAL CO LTD | 2015-10-21 | — | — | CN | claimed |
| US-20260125365-A1 | TRIAZINE DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SHIONOGI & CO., LTD. (JP) | 2026-05-07 | — | — | US | disclosed |
| CN-1079962-A | New substituted tertiary amine compound and salt thereof | YAMANOUCHI PHARMA CO LTD (JP) | 1993-12-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125365-A1 | TRIAZINE DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ACE2, ACE, SARS1 | DPP4 6/4885HDAC1 120/4885HDAC8 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.